|31st December 2020||David G Foster||11,052||Open or private sale||$6.38||$70,511.76|
|31st December 2020||Anna Berkenblit||2,203||Grant/award etc.||$4.04||$8,900.12|
|31st December 2020||David G Foster||362||Grant/award etc.||$4.04||$1,462.48|
|31st December 2020||David G Foster||27,240||Exercise of derivative||$0.00|
|31st December 2020||Theresa Wingrove||2,659||Grant/award etc.||$4.04||$10,742.36|
|1st July 2020||David G Foster||342||Grant/award etc.||$3.91||$1,337.22|
|30th June 2020||Anna Berkenblit||3,047||Grant/award etc.||$3.91||$11,913.77|
|30th June 2020||Mark J Enyedy||5,241||Grant/award etc.||$3.91||$20,492.31|
|30th June 2020||Thomas Ryll||5,241||Grant/award etc.||$3.91||$20,492.31|
|30th June 2020||Theresa Wingrove||2,593||Grant/award etc.||$3.91||$10,138.63|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.
ImmunoGen, Inc. was founded in March 1981 and is headquartered in Waltham, MA. Its product candidates include Mirvetuximab soravtansine, Coltuximbe ravtansin, IMGN7779 and IMGN632.